These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 20027193)

  • 21. Aldosterone and the risk of hypertension.
    Xanthakis V; Vasan RS
    Curr Hypertens Rep; 2013 Apr; 15(2):102-7. PubMed ID: 23378101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aldosterone as a mediator in cardiovascular injury.
    Stier CT; Chander PN; Rocha R
    Cardiol Rev; 2002; 10(2):97-107. PubMed ID: 11895576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aldosterone and aldosterone synthase inhibitors in cardiorenal disease.
    Verma S; Pandey A; Pandey AK; Butler J; Lee JS; Teoh H; Mazer CD; Kosiborod MN; Cosentino F; Anker SD; Connelly KA; Bhatt DL
    Am J Physiol Heart Circ Physiol; 2024 Mar; 326(3):H670-H688. PubMed ID: 38133623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High Frequency of Variants of Candidate Genes in Black Africans with Low Renin-Resistant Hypertension.
    Jones ES; Spence JD; Mcintyre AD; Nondi J; Gogo K; Akintunde A; Hackam DG; Rayner BL
    Am J Hypertens; 2017 May; 30(5):478-483. PubMed ID: 28052878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening Rates for Primary Aldosteronism in Resistant Hypertension: A Cohort Study.
    Jaffe G; Gray Z; Krishnan G; Stedman M; Zheng Y; Han J; Chertow GM; Leppert JT; Bhalla V
    Hypertension; 2020 Mar; 75(3):650-659. PubMed ID: 32008436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mineralocorticoid antagonism and cardiac hypertrophy.
    Nagata K
    Curr Hypertens Rep; 2008 Jun; 10(3):216-21. PubMed ID: 18765093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Familial hyperaldosteronism.
    Torpy DJ; Stratakis CA; Chrousos GP
    Braz J Med Biol Res; 2000 Oct; 33(10):1149-55. PubMed ID: 11004715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stress-induced Aldosterone Hyper-Secretion in a Substantial Subset of Patients With Essential Hypertension.
    Markou A; Sertedaki A; Kaltsas G; Androulakis II; Marakaki C; Pappa T; Gouli A; Papanastasiou L; Fountoulakis S; Zacharoulis A; Karavidas A; Ragkou D; Charmandari E; Chrousos GP; Piaditis GP
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2857-64. PubMed ID: 25974737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aldosterone/renin ratio determines peripheral and central blood pressure values over a broad range.
    Tomaschitz A; Maerz W; Pilz S; Ritz E; Scharnagl H; Renner W; Boehm BO; Fahrleitner-Pammer A; Weihrauch G; Dobnig H
    J Am Coll Cardiol; 2010 May; 55(19):2171-80. PubMed ID: 20447545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Syndromes that Mimic an Excess of Mineralocorticoids.
    Sabbadin C; Armanini D
    High Blood Press Cardiovasc Prev; 2016 Sep; 23(3):231-5. PubMed ID: 27251484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic alterations in patients with primary aldosteronism.
    Takeda Y
    Hypertens Res; 2001 Sep; 24(5):469-74. PubMed ID: 11675938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome of adrenal vein sampling performed during concurrent mineralocorticoid receptor antagonist therapy.
    Haase M; Riester A; Kröpil P; Hahner S; Degenhart C; Willenberg HS; Reincke M
    J Clin Endocrinol Metab; 2014 Dec; 99(12):4397-402. PubMed ID: 25222758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hyperaldosteronism].
    Scholl UI
    Internist (Berl); 2021 Mar; 62(3):245-251. PubMed ID: 33599784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is altered adrenal steroid biosynthesis a key intermediate phenotype in hypertension?
    Connell JM; Fraser R; MacKenzie S; Davies E
    Hypertension; 2003 May; 41(5):993-9. PubMed ID: 12654713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aldosterone Synthase Inhibitors and the Treatment of Essential Hypertension.
    Gomez-Sanchez CE; Gomez-Sanchez EP
    J Clin Endocrinol Metab; 2023 Jul; 108(8):e638-e639. PubMed ID: 36740773
    [No Abstract]   [Full Text] [Related]  

  • 36. Evolving role of aldosterone blockers alone and in combination with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in hypertension management: a review of mechanistic and clinical data.
    Black HR
    Am Heart J; 2004 Apr; 147(4):564-72. PubMed ID: 15077068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of the renin-angiotensin-aldosterone system in collecting duct-derived endothelin-1 regulation of blood pressure.
    Ge Y; Huang Y; Kohan DE
    Can J Physiol Pharmacol; 2008 Jun; 86(6):329-36. PubMed ID: 18516095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aldosterone and refractory hypertension.
    Nyirenda MJ; Padfield PL
    Curr Opin Endocrinol Diabetes Obes; 2007 Jun; 14(3):213-8. PubMed ID: 17940442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic determination of plasma aldosterone levels in essential hypertension.
    Pojoga L; Gautier S; Blanc H; Guyene TT; Poirier O; Cambien F; Benetos A
    Am J Hypertens; 1998 Jul; 11(7):856-60. PubMed ID: 9683048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variation at the aldosterone synthase (CYP11B2) locus contributes to hypertension in subjects with a raised aldosterone-to-renin ratio.
    Lim PO; Macdonald TM; Holloway C; Friel E; Anderson NH; Dow E; Jung RT; Davies E; Fraser R; Connell JM
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4398-402. PubMed ID: 12213905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.